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1.0 National Office of Public Health Genomics 
Public health genomics is a multidisciplinary field concerned with the effective and 
responsible translation of genome-based knowledge and technologies to improve population 
health. Public health genomics uses population-based data on genetic variation and gene-
environment interactions to develop evidence-based tools for improving health and 
preventing disease. 
Through the National Office of Public Health Genomics (NOPHG), the Centers for Disease 
Control and Prevention (CDC) provides national and international leadership in public heath 
genomics, while building partnerships with other federal agencies, state health departments, 
public health organizations, professional groups, and the private sector. 
1.1 Vision, Mission, and Goals 
The vision, mission, and goals of NOPHG have evolved over time in response to 
ongoing input from internal and external CDC partners; lessons learned from 
NOPHG initiatives; priorities of CDC agency-wide initiatives, including the Goals 
Process and the Futures Initiative; and the changing identity and location of the office 
within CDC’s organizational structure. The central tenet upon which NOPHG’s vision, 
mission, and goals is based is the role of public health in translating human genome 
discoveries into population health benefits. 
Although fundamental to many CDC programs, legislation has not been the primary 
influence in directing specific NOPHG activities. Instead, priorities are continually 
shaped by NOPHG leadership, input from internal and external CDC partners, the 
roles of other government agencies and the private sector, availability of funding, and
the state of the science. NOPHG’s research and program portfolios are dedicated to 
closing the gap between genome discoveries and public health impact.
Vision: 
To use genomic knowledge to improve the lives and health of all people. 
Mission: 
To integrate genomics into public health research, policy, and programs. 
Goals: 
To improve public health interventions of diseases of major public health
importance, including chronic, infectious, environmental, and occupational  
diseases, through population-based genomic research, assessment of the role of  
family history in determining risk and preventing disease, and the evaluation of  






















1.2 Major Initiatives 
Evaluation of Genomics Applications for Practice and Prevention 
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) 
initiative was launched by NOPHG to establish and test a systematic, evidence-
based process for evaluating genetic tests and other applications of genomic 
technology that are in transition from research to clinical and public health practice. 
Family History Public Health Initiative
NOPHG started the Family History Public Health Initiative in 2002 to increase 
awareness of family history as an important risk factor for common chronic diseases 
such as cancer and diabetes, and to promote its use in programs aimed at reducing 
the burden of these diseases in the U.S. population. 
Human Genome Epidemiology Network
NOPHG established the Human Genome Epidemiology Network (HuGENet™) in 
1998 to help translate genetic research findings into opportunities for preventive 
medicine and public health by advancing the synthesis, interpretation, and 
dissemination of population-based data on human genetic variation in health and 
disease. 
NHANESIII Collaborative Genomics Project 
In 2002, NOPHG formed a multidisciplinary working group with members from 
across CDC to develop a proposal to measure the prevalence of selected genetic 
variants of public health significance in a representative sample of the U.S. 
population and to examine the associations between the selected genetic variants 
and disease outcomes available in NHANES III data.  
Public Health Genomics Capacity Building 
Since 2005, NOPHG has funded Centers for Genomics and Public Health within 
schools of public health at the Universities of Michigan and Washington to provide 
expertise in translating genomic information into useable public health knowledge, to 
provide technical assistance to state and community public health agencies, and to 
integrate genomics into programs and practice.
Since 2003, NOPHG has supported genomics programs in four state health
departments (Michigan, Minnesota, Oregon, and Utah) to integrate genomics 
knowledge (e.g., genetic risk factors) and tools (e.g., family history assessments) into 
chronic disease prevention programs and core public health functions.  
Public Health Investigations 
NOPHG and the National Center for Influenza and Respiratory Diseases developed 
the Influenza Public Health Genomics Initiative in 2006 to investigate the role of 
population genetic variation in the epidemiology of influenza morbidity and mortality 
and the effectiveness of public health interventions. 
In 2006, NOPHG provided seed funding for 11 innovative CDC projects, focusing on
infectious disease, chronic disease, birth defects, pharmacogenomics, and 
environmental exposures, to integrate genomics into their research and programs. 
Nine of these initiatives were funded in 2007, for a second year, with anticipated 














2.0 Organization and Staffing 
Dr. Muin J. Khoury, NOPHG director, and Scott Bowen, deputy director, provide strategic 
leadership for NOPHG with support and input from the associate director for epidemiology, 
Dr. Marta Gwinn, and the associate director for science, Dr. Ralph Coates, and the other 
senior staff. Day-to-day operations are supported by management and operations staff. 
NOPHG has dedicated teams to support its major projects and communication functions. 
These teams include: the Knowledge Integration Team; the Population Health Research 
Team; the EGAPP Team; the Prevention and Translation Research Team; and the 
Communications Team. Each team has a designated lead staff member and support staff. 
The organizational structure, depicted in the figure below, includes personnel who possess 
a wide array of professional disciplines and skills. Currently, NOPHG supports a total of 45 
staff, including 18 federal full-time employees (and four vacancies). 
3.0 Strategic Accomplishments in FY2007 
Advances in genomics have led to mounting expectations for the translation of genomic 
research into applications for health care and disease prevention. A comprehensive agenda 
for translation research and surveillance is needed to move human genome discoveries into 
health practice in a way that maximizes health benefits and minimizes harm to individuals 
and populations. Currently, hundreds of thousands of genetic variants are being evaluated 
for association with common, chronic diseases. Research is accelerating the use of new 
biomarkers derived from gene expression, proteomic, and other “omic” technologies. The 
number of genetic tests used in clinical practice and research is increasing. In addition, 
family medical history is receiving renewed attention as a genomic and public health tool for 



























3.1 External Peer Review
In the past decade, NOPHG has established public health genomics as an interdisciplinary 
field and developed strong collaborations to begin closing the gap between gene discoveries 
and population health benefits. To obtain scientific review and assessment of NOPHG 
research and public health initiatives, NOPHG held an external peer review panel in August 
2007. Public health experts Deborah Klein Walker, EdD, Norman Kahn, MD, Joann 
Boughman, PhD, Charles Rotimi, PhD, and Alan Guttmacher, MD participated in the review 
panel. NOPHG presented an overview of CDC’s work in public health genomics during the 
last 10 years, summaries of the current major NOPHG initiatives, and NOPHG’s vision for 
the next decade. Directors and management staff from CDC’s Coordinating Center for 
Health Promotion, the National Center for Chronic Disease Prevention and Health 
Promotion, and other CDC centers participated in this event.  
The external peer review panel developed the following program recommendations to
strengthen NOPHG’s strategy, goals, and initiatives: 
•	 Focus on activities that help move genomics from research to practice.  
•	 Continue and expand the current seed grant program.  
•	 Expand the family history project by adding a translational research dimension.  
•	 Undertake a specific proof-of-principle study to illustrate the value of genomic-based 
education among providers and patients.  
•	 Investigate ways to incorporate translational research initiatives into existing 
practice-based research networks.   
•	 Continue the Evaluation of Genomics Applications in Practice and Prevention 
(EGAPP) initiative to ensure appropriate evaluation of newly available genetic tests. 
•	 Sustain the HuGENet project. 
•	 Partner with existing provider groups and end-users of genomic data to determine 
the utility of specific types of genomic data and activities.  
•	 Continue work on the Beyond Gene Discovery initiative using NHANES III data.  
•	 Focus on communicating CDC’s unique role in the field of genomics.  
•	 Develop logic models to help elucidate program effectiveness over time.   
•	 Expand efforts to educate other CDC units about the field of genomics.  
•	 Continue leadership in infusing genomics into public health practice at the state and
local levels. 
•	 Reposition NOPHG within existing organizational structure of CDC. 
•	 Continue to collaborate on international genomics initiatives. 
NOPHG is making strides to ensure that these recommendations are incorporated into its 
current strategic plan, focusing on genomics initiatives that are most critical for public health 
and clinical practice, and developing new ways to increase investment in public health 












   











3.2 Strategic Plan for Translation Research 
In 2007, NOPHG continued to develop its portfolio for translation research and surveillance 
activities to advance knowledge about the validity, utility, utilization and population health 
impact of genomic applications and family history for improving health and preventing 
disease in well-defined populations or practice settings. The objective is to address key 
questions along the translation continuum, from 1) the initial development and evaluation of 
candidate genomic applications, to 2) thorough evaluation of the genomic applications and 
development of evidence-based clinical practice guidelines for the use those applications, to 
3) the dissemination and implementation of recommended applications in clinical and public 
health practice, to 4) the evaluation of the extent and fidelity with which recommended 
applications are implemented in community settings and the effect of implementation on 
population health.  
4.0 Scientific Highlights in FY2007 
This section provides a summary of NOPHG’s major scientific highlights in FY2007. 
References to scientific publications by NOPHG are provided.   
4.1 Evaluation of Genomic Applications in Practice and Prevention (EGAPP) 
EGAPP activities are focused around the independent, non-federal EGAPP 
Working Group established in May 2005.  The roles of this multidisciplinary panel 
include optimization of methods and processes for evidence review to deal with
complex and rapidly emerging technologies; identification, prioritization and 
selection of topics; participation on technical expert panels that guide conduct of
evidence reports; and development of recommendation statements for clinicians
based on the evidence. 
In FY2007, four CDC-funded evidence reports were completed for the EGAPP 
Working Group by Evidence-Based Practice Centers (EPCs), through an interagency 
agreement with the Agency for Healthcare Research and Quality (AHRQ): 
• Genomic Tests for Ovarian Cancer Detection and Management
(www.ahrq.gov/clinic/tp/genovctp.htm) 
•	 Testing for Cytochrome P450 (CYP450) Polymorphisms in Adults With Non-
Psychotic Depression Treated With Selective Serotonin Reuptake Inhibitors 
(SSRIs) (www.ahrq.gov/clinic/tp/cyp450tp.htm) 
•	 Hereditary Nonpolyposis Colorectal Cancer: Diagnostic Strategies and Their 
Implications (http://www.ahrq.gov/clinic/tp/hnpcctp.htm) 
•	 Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes  
(pending release by AHRQ) 
Another non-EPC report, Can UGT1A1 Genotyping Reduce Morbidity and Mortality 
in Patients with Metastatic Colorectal Cancer Treated with Irinotecan?, and a 
supplemental report, DNA Testing Strategies Aimed at Reducing Morbidity and 





    
    



















Based on consideration of the availability and quality of evidence and clinical and
social contextual issues, the Working Group develops recommendation statements
that summarize current knowledge, provides guidance on appropriate use, and 
defines key gaps and needed research. In FY2007, the first in a series of EGAPP
Working Group recommendation statements, on CYP450 testing in patients with
depression treated with SSRIs, was accepted for publication in Genetics in 
Medicine (December 2007 issue). 
Other EGAPP accomplishments for FY2007 include the establishment, with NOPHG 
support, of the EGAPP Stakeholders Group, and the independent website 
(www.egappreviews.org), which hosts products of the EGAPP Working Group. 
4.2 Family History Public Health Initiative 
Family History Analyses 
To assess the risk of common chronic diseases and conditions in the U.S. population 
attributable to family health history, NOPHG analyzed data collected through the 
National Health and Nutrition Examination Survey (NHANES). NOPHG stratified the
U.S. population in three levels of familial risk (average, moderate, and high) and 
examined the association between risk and the prevalence of specific diseases.   
NOPHG found that several studies indicate that the risk for type 2 diabetes or 
cardiovascular disease is detectable in childhood, although these disorders may not 
emerge until adulthood. A simple way to detect risk for either diabetes or 
cardiovascular disease is to examine the family history. Numerous studies have 
shown that adults who have one or more first- or second-degree relatives affected 
with diabetes or cardiovascular disease are at high risk of having or developing these
diseases. Although there are currently no overall screening strategies recommended
for either disease among children or adolescents, family history should become part 
of prevention campaigns aimed at reducing the burden of these diseases and their 
risk factors in children. 
NOPHG found that family history of diabetes has a significant, independent, and 
graded association with the prevalence of diabetes in the U.S. population. 
Independently of sex, race/ethnicity, age, BMI, hypertension, income, and education,
people in the moderate and high familial risk categories for diabetes were 2.3 and 
5.5 times more likely to have diabetes, respectively, than people in the average risk 
category. 
In another study of the U.S. population, NOPHG found that a positive family history 
of osteoporosis was present in 19.8% of women aged 20 years or older. Women 
aged 35 years or older with a positive family history of osteoporosis were 2.3 times 
more likely to have the disease. The association grew stronger (to 8.4 times) when 
two or more close relatives affected with osteoporosis had a family history of the 
disease. 
Publications: 
Valdez R, Greenlund KJ, Khoury MJ, Yoon PW. Is family history a useful tool for 
detecting children at risk for diabetes and cardiovascular diseases? A public health
























Valdez R, Yoon P, Liu K, Khoury MJ. Family history and prevalence of diabetes in 
the U.S. population: The 6-year results from the National Health and Nutrition 
Examination Survey (1999-2004). Diabetes Care 2007;30:2517-2522.
Manuscript in clearance:
Robitaille J, Yoon PW, Irizarry-Delacruz M, Liu T, Moore CA, Looker AC, Khoury MJ. 
Prevalence, Family History, and Prevention of Reported Osteoporosis in U.S. 
Women. 
Family Healthware™ 
In October 2007, three NOPHG-sponsored research centers at the University of 
Michigan School of Medicine, Evanston Northwestern Healthcare Research Institute,
and Case Western Reserve University School of Medicine completed data collection 
for an evaluation study of the Family Healthware™ tool. This web-based tool 
provides users with a familial risk assessment for six chronic conditions (breast, 
colorectal, and ovarian cancer, coronary heart disease, diabetes, and stroke) and a 
“prevention plan” containing personalized recommendations for lifestyle changes and 
screening recommendations. Researchers of the Family Healthware™ study are 
currently developing manuscripts on the study methodology and health risk 
perceptions of family history and chronic diseases. NOPHG is currently collaborating 
with NIH to test Family Healthware™ in a longitudinal clinical trial as part of a new 
effort to combine Family Healthware™ with the U.S. Surgeon General’s tool “My 
Family Health Portrait.”  
4.3 Human Genome Epidemiology Network (HuGENet™) 
HuGENet™ Collaboration 
HuGENet™ has continued to grow as an open collaboration of individuals and 
organizations from around the world. In FY2007, a HuGENet™ Short Course was 
offered in the United Kingdom and a HuGENet™ Workshop on the Assessment of 
Cumulative Evidence on Genetic Associations was held in Italy. 
HuGE Publications  
HuGENet™ has a leadership role in promoting study approaches and methods that 
lead to synthesis and translation of population-based genomic research data. In 
FY2007, HuGENet™ collaborators published 14 articles on these topics in scientific 
journals, including the American Journal of Epidemiology, the International Journal of
Epidemiology, and PLoS Medicine. 
Publications: 
Ioannidis JPA, Boffetta P, Little J, O’Brien TR, Uitterlinden AG, Vineis P, et al. 
Assessment of Cumulative Evidence on Genetic Associations: Interim Guidelines. Int 
J Epidemiol 2007;Sep 26 [Epub ahead of print]. 
Yu W, Yesupriya A, Wulf A, Qu J, Khoury MJ, and Gwinn M. An open source 























domain-specific subset of PubMed, with an example from human genome 
epidemiology. BMC Bioinformatics 2007;8:436.  
HuGE Reviews 
HuGE Reviews are systematic, peer-reviewed assessments of gene-disease 
association studies conducted by health researchers affiliated with the Human 
Genome Epidemiology Network (HuGENet™). HuGE Reviews typically point to gaps 
in existing epidemiologic and clinical knowledge, thus stimulating further research in 
these areas. These reviews are published in partnership with 10 scientific journals. In 
FY2007, 11 HuGE Reviews were published by authors affiliated with institutions in 
the U.S. and five other countries, reflecting the global reach of HuGENet™. Through 
special agreements with the journals, HuGE reviews are available free of charge on 
the HuGENet™ web pages of NOPHG’s website 
(www.cdc.gov/genomics/hugenet/reviews). 
HuGE Navigator 
In September 2007, NOPHG launched the HuGE Navigator, which is an up-to-date 
online knowledge base on human genome epidemiology, including information on 
the population prevalence of genetic variants, gene-disease associations, gene-gene 
and gene-environment interactions, and the evaluation of genetic tests. HuGE 
Navigator is intended primarily for researchers in public health genomics and other 
related disciplines and includes the following applications:  
•	 HuGE Literature Finder, a database curated by NOPHG that includes 
abstracts from approximately 30,000 published articles on human genome 
epidemiology, extracted from PubMed. These articles reference about 3,000 
genes and 3,500 diseases and conditions. 
•	 HuGE Investigator Browser, which allows users to identify investigators in a 
particular field of human genome epidemiology. 
•	 GeneSelectAssist, a search engine for finding possible candidate genes 
based on the NCBI Entrez Gene, PubMed and HuGE Pub Lit databases.
•	 HuGE Risk Translator, a tool for calculating the expected predictive value of 
genetic markers. 
•	 HuGE Watch, a tool for tracking the evolution of published literature in  

human genome epidemiology.  

•	 HuGEpedia, an online encyclopedia of human genetic variation and health
information that is currently in development. 
HuGE Navigator can be accessed at (www.hugenavigator.net/).
Publication:
Yu W, Yesupriya A, Wulf A, Qu J, Gwinn M, Khoury MJ. An automatic method to 
generate domain-specific investigator networks using PubMed abstracts. BMC Med 


















4.4 NHANES III Collaborative Genomics Project 
Determination of the prevalence of genetic polymorphisms of public health 
importance in the U.S. population, and in subgroups of the population, is a critical
first step in evaluating the genetic epidemiology of complex diseases. Such data 
would be an invaluable resource for: 1) investigations into U.S. population structure; 
2) calculations of population attributable fraction(s) of the U.S. burden of disease 
associated with genetic variation and gene-environment interaction; and 3) 
assessment of the potential for screening population subgroups for genes that confer 
susceptibility to disease. In addition, population-based allele and genotype 
prevalence data would also serve as a reference for researchers to use in designing
future association studies.  
Genotyping of Gene Variants of Public Health Importance 
In FY2007, NCI and CDC laboratories completed the genotyping of 90 variants in 50
genes, and successfully deposited the results at the National Center for Health 
Statistics (NCHS). Statistical analysis for each of the approximately 35 genotype-
phenotype correlation studies is in progress at NCHS. 
CDC/NCI NHANES Working Group 
The CDC/NCI Working Group has written the first manuscript entitled “Prevalence in 
the United States of Variants in Genes of Public Health Importance: Third National 
Health and Nutrition Examination Survey (NHANES III), 1991-1994.” NOPHG 
statisticians and analysts are also preparing a second manuscript describing the 
statistical methods that have been developed for use in complex surveys including 
genetic data. The CDC/NCI Working Group are reviewing their preliminary data 
analyses and finalizing their analytic plans for genotype-phenotype association 
analyses of the NCHS genotype-phenotype correlation studies. 
Manuscript in clearance:
Chang M, Lindegren ML, Butler MA, Chanock SJ, Dowling NF, Gallagher M, 
Moonesinghe R, Moore CA, Ned RM, Reichler M, Sanders CL, Welch R, Yesupriya 
A, and Khoury MJ. Prevalence in the United States of Variants in Genes of Public 
Health Importance: Third National Health and Nutrition Examination Survey 
(NHANES III), 1991-1994.
Beyond Gene Discovery (BGD) Working Group 
In FY2007, NOPHG established a Beyond Gene Discovery (BGD) Working Group, 
with representation from all centers at CDC, which will use a whole-genome 
approach (approximately one million SNPs and copy number variants) to assess the 
prevalence of genetic polymorphisms in the NHANES III DNA Bank. Completion of 
this project will enhance the value of many ongoing gene discovery studies, helping 
to translate their findings into new targets for prevention, diagnosis, and treatment of 
common diseases, and will provide the basis for estimating the number of people 
who may benefit from particular genotype-based screening or diagnostic tests, 








    
 
    
     














4.5 Other NOPHG Scientific Highlights 
National Surveys of Direct-To-Consumer Nutrigenomic Tests 
In 2006, NOPHG utilized two national surveys—HealthStyles and DocStyles—to 
assess U.S. consumer awareness and use of direct-to-consumer (DTC) 
nutrigenomic tests (HealthStyles), and to assess knowledge of and experiences with 
these tests among U.S. physicians (DocStyles). NOPHG found that 14% of 
consumers were aware of nutrigenomic tests, and 0.6% reported using them. 44% of 
physicians were aware of these tests, and of those, 41% had never had a patient ask 
about such tests, and 74% had never discussed the results of a nutrigenomic test 
with a patient. 
Until now, no national baseline information has been available regarding public 
awareness, interest in, or use of DTC nutrigenomic tests. Likewise, information is 
scarce regarding health care providers’ knowledge, attitudes, and experiences with 
DTC nutrigenomic tests. This information provides insight into the public demand for 
such tests and the potential for harm and, as additional information is collected over 
time, will provide a historical reference of trends in awareness and use. In addition, 
baseline information can be tracked longitudinally to assess the impact of policies, 
efforts at public and provider education, and the evolution of the availability and 
demand for such test. 
Publication:
Goddard KAB, Moore C, Ottman D, Szegda KL, Bradley L, Khoury MJ. Awareness 
and use of direct-to-consumer nutrigenomic tests, United States, 2006. Genet Med. 
2007 Aug;9(8):510-7. 
Public Health Genomics Seminar Series 
During FY2007, NOPHG organized a public health genomics seminar series, “Public 
Health Genomics: Closing the Gap Between Human Genome Discoveries and 
Population Health,” in partnership with the National Cancer Institute, the National 
Human Genome Research Institute, the National Institute for Child Health and 
Development, and the Office of Behavioral and Social Sciences Research. The goal 
of this seminar series is to educate health researchers and practitioners in public 
health genomics. The series explores various topics at the intersection of genetics, 
medicine, and public health, and the contributions of the multidisciplinary field of 
public health genomics to the translation of gene discoveries into population health 
benefits. 
From January to October 2007, eight seminars were conducted on these topics:   
•	 What is public health genomics and why should we care? An overview of the 
series 
•	 How do we assess the contribution of complex genotypes and gene-
environment interaction to the population burden of common diseases?
•	 What is the role of behavioral and social sciences in translating genetic 
research into population health benefits? 
























•	 Knowledge integration in public health genomics: evaluation of genetic and 
genomic tests 
•	 But how do we translate new genetic knowledge into practice? 
•	 How do we actually translate guidelines into action? 
•	 How do we monitor the impact of genomics on population health?  
•	 Can we use family history as a tool for disease prevention and public health? 
•	 Can Genomics help heal the schism between medicine and public health? 
The last seminar is planned for November 29th, 2007, and will focus on “Genomics 
and the schism between basic sciences, medicine and public health.” 
This seminar series is conducted at NIH and broadcast live at CDC. Videocasts and 
slides of the presentations and selected articles are available as a resource on 
NOPHG’s website: (www.cdc.gov/genomics/events/special1.htm) 
Influenza Public Health Genomics Workshop
In January 2007, NOPHG and National Center for Immunization and Respiratory 
Diseases held a workshop to discuss opportunities for public health research on the 
role of human genomics in influenza disease and vaccine response. More than 100 
participants from diverse fields—including immunology, virology, epidemiology, 
medicine and public health—working in government, academia, and private-sector 
research organizations attended the workshop. The workshop concluded by 
proposing priorities for genomics research on determinants of influenza disease 
severity and vaccine response and side effects. 
5.0 NOPHG-Funded State Achievements in FY2007 
The following are examples of achievements in FY2007 of the state genomics programs in 
Michigan and Minnesota. 
5.1 Michigan Department of Community Health  
Public Health Issue 
Sudden cardiac death (SCD) is defined as an unexpected sudden death due to a 
cardiac cause and occurring within one hour of the onset of symptoms in an 
individual who had been in his/her usual state of health, without any known life-
threatening condition. SCD can be especially devastating when it occurs in children,
youth, or young adults in the prime of life who were previously thought to have been 
in good health. The Michigan Department of Community Health (MDCH) Genomics 
Program has identified sudden cardiac or unexplained death of the young (under age 
30) as a potentially preventable condition, due to the heritable nature of certain 
cardiac disorders. Specific causes of SCD in younger adults and children are more 
likely to have genetic determinants than similar conditions in older persons. These 
include etiologies such as inherited arrhythmias, hypertrophic cardiomyopathy, 
undetected congenital heart defects, and early atherosclerotic heart disease. 
Program Example 
In an effort to learn more about the burden of SCD of the young in Michigan, the 











Section and Michigan State University, initiated a pilot mortality review system in 
early summer 2007. The goal of this project is to reduce the burden of SCD of the 
young in Michigan by identifying health care system changes and family-based 
interventions for increasing awareness and prevention among individuals at 
increased risk. The mortality review system utilizes multiple avenues to gather 
information; mortality data are obtained from MDCH Division for Vital Records and 
Health Statistics. The SCD case definition includes decedents who were Michigan 
residents, aged 1-29 years, who died outside of the hospital or in an emergency 
department, and had specific cardiac or ill-defined causes of death recorded as the 
underlying cause of death on their death certificate.  
For select cases who died between October 2006 and March 2007, medical records 
for the day of death and for the year prior to death were requested from providers 
and health care facilities. Selected decedents’ next-of-kin were contacted and asked 
to participate in an interview regarding the events surrounding the death. Four 
anonymized case summaries were prepared and an advisory panel of 13 members, 
with varied genetics, cardiac, and medical expertise, was convened in October 2007 
to review the cases and provide feedback on the etiologic nature of the deaths, 
implications for family members, and the mortality review process. 
Implications and Impact 
In 2006, a total of 83 deaths met the SCD case definition, translating to an estimated 
mortality rate of 2.1 per 100,000 for individuals 1-29 years of age. Black men were 
disproportionately affected. Almost one-third of the total cases died of 
cardiomyopathy. About half of the total cases died in an emergency department, 
while the other half died elsewhere. The SCD advisory panel found several 
implications for immediate family members of three out of the four cases that were 
reviewed during the panel meeting. Recommendations made by the advisory panel 
will be used to modify the case definition, improve the review process, and guide 
ongoing efforts to develop evidence-based public health recommendations for 
preventing SCD of the young in Michigan. This project is expected to increase 
knowledge of factors that contribute to SCD and feasibility of using mortality data to 
identify family, public, and provider needs regarding SCD. 
▪ ▪ ▪ ▪ ▪ ▪ ▪
Public Health Issue 
In 2006-2007, the MDCH Genomics Program partnered for the first time with the 
MDCH Division of Environmental Health to integrate genomics and family history 
principles into a project called Health Homes University (HHU). This projects aims to 
positively affect the knowledge, attitudes, and behaviors of families to reduce asthma 
triggers and potential injury sources within their homes, to reduce emergency-care 
events related to asthma and injury, and to reduce school absenteeism. To date, 
more than 200 families have enrolled in the program. Family history is an important 
known risk factor for asthma. A family history of asthma has also been associated
with asthma severity. 
Program Example 
The MDCH Genomics Program integrated questions into the HHU baseline survey 















number of family members in the household and those who had asthma, severity of 
asthma, and knowledge of asthma triggers. Family history information from 162 
families showed that 65% of probands (affected child) had at least one first-degree 
relative who had ever been diagnosed with asthma. When expanded to include 
second-degree relatives, this number rose to 77%.  
The results from the baseline interview showed a significant trend of an increasing 
number of affected first-degree relatives associated with increasing days reported 
with asthma symptoms (e.g., shortness of breath, wheezing). Children with one or 
more first-degree relatives ever diagnosed with asthma had more days with 
symptoms on average than children without a first-degree family history.
Implications and Impact 
By identifying households with multiple family members with asthma and educating 
these family members about asthma triggers in the home, the number of persons 
with asthma and/or the frequency and severity of asthma are expected to decline in 
these households. 
5.2 Minnesota Department of Health 
Public Health Issue 
The integration of genomics into public health requires an educated and skilled 
workforce capable of interpreting and applying relevant genomic and family history 
information to research and practice settings and policy development. 
Program Example 
The Minnesota genomics program collaborated with the University of Minnesota’s 
School of Public Health to organize three new courses and a roundtable session on 
public health genomics as part of the 6th annual Summer Public Health Institute from 
May 21 to June 8, 2007. Courses on “Genomics in Public Health,” and “Application of
Genomics to Public Health Part 1, and Part 2” provided an overview of basic human
genetics and genomics, and a survey of the opportunities and challenges for using 
these disciplines in public health research and practice. The roundtable session 
focused on “Genes and the Environment: The Emerging Role of Genomics in Public 
Health.” Muin Khoury, MD, PhD, director of the National Office of Public Health 
Genomics at the Centers for Disease Control presented on gene-environment 
interactions and the emerging role of genomics in public health during this session. 
More information about the Summer Public Health Institute is available at
http://cpheo.sph.umn.edu/cpheo/institute/home.html, and more information about the 
roundtable session is available at: 
http://www.sph.umn.edu/cpheo/events/roundtable/Roundtable_060807.html. 
Implications and Impact 
The Public Health Institute courses were nationally advertised and over 300 
participants attended from 28 states and five countries. Total enrollment for the 
genomics courses was 27, and included participants from Illinois, Michigan, 
Minnesota, North Dakota and Oregon. An additional 100 public health practitioners,
health care providers, faculty, students, and other professionals attended the 
roundtable and there were over 325 “hits” recorded on the roundtable website. 





















6.0 Future Directions 
Our vision for public health genomics at CDC in the next decade is to accelerate the 
evaluation and appropriate integration of new genomic knowledge into CDC goals and 
actions. During the past two years, CDC has developed new goals for achieving greater 
health impact in the U.S. These goals are framed in the context of life stages, places, 
preparedness, and global health. Progress toward this vision will be accomplished in two 
overlapping phases over the next 10 years: 
Phase I: During the next five years, NOPHG plans to accelerate research and development 
of new information and tools for use by the public and the health care community. Specific 
approaches and products will include a human genome profile of the U.S. population, family 
history tools, genetic test evaluations, and dissemination of translational materials to the 
public and providers. CDC will fund intramural and extramural research on genomics and 
population health. 
Phase II: During the following five years, NOPHG envisions a phased approach for 
integrating genomic information into public health programs that promotes health and 
prevents disease. When evidence-based recommendations are developed, NOPHG will 
work with CDC programs to integrate them into guidance and programs conducted by CDC 
and its partners in the public health and clinical communities.  
NOPHG will spearhead an ongoing assessment of CDC’s public health genomics capacity 
(laboratory, informatics, training, etc). With additional resources, we will try to fill gaps in
infrastructure in order to meet the challenge of public health genomics in the next decade. 
Expansion of Collaborative NOPHG Initiatives 
The next 10 years of public health genomics at CDC will focus on: 
•	 Accelerating the process of translation to close the widening gap between basic 
research and application, 
•	 Synthesizing and integrating knowledge for better decision making, 
•	 Engaging, educating, and empowering consumers and providers, 
•	 Expanding and leveraging partnerships to enhance the integration of genomics 
across all areas of health and health care, and  
•	 Expanding international collaborations in public health genomics. 
The following section describes proposed NOPHG collaborative initiatives for the next 10 
years that build on the success and achievements of ongoing initiatives. The diagram below 
shows how these initiatives are designed to begin to close the gap between gene 














Beyond Gene Discovery (BGD) 
With the completion of the Human 
Genome Project and the emerging 
availability of genomic technologies to
measure human genetic variation, CDC 
and the CDC Foundation are launching 
a new initiative, BGD. In collaboration 
with public, private, and academic 
partners, the initiative will assess 
population genetic variation in the U.S. 
in relation to health and disease and
develop strategies for using genetic 
information to impact health and 
eliminate disparities among population 
groups. NHANES provides a unique national resource for investigating the effects of genetic 
variation on health and will serve as the initial focus of BGD. Genetic samples are available 
for nationally representative probability samples of approximately 15,000 persons enrolled in 
two NHANES (about 7,000 participants in NHANES III from 1991 to 1994 and 8,000 
participants in NHANES 1999–2002). The survey over samples the two largest race/ethnic 
minority groups, non-Hispanic blacks and Mexican Americans along with other subgroups of 
the population. Information on multiple aspects of health obtained through interview, 
laboratory tests, and direct examinations is also available for the NHANES participants. 
BGD is the first large-scale effort in the U.S. to support comprehensive identification of the 
associations among variations in genotype, phenotype, and risk factors in a representative 
sample of the population, laying the groundwork for understanding the relation between 
human genome variation and health status. 
BGD has the following overarching, three-year goals: 
•	 Produce the first comprehensive report of the “Genome Profile of the United States” 
population, a summary of the prevalence of common genetic variants in the U.S., 
including racial and ethnic population groups. 
•	 Support the development of a searchable, online information system of human 
genome variation (allele, genotype and haplotype frequencies at individual and 
multiple genetic loci) that is readily accessible to researchers, health care providers 
and policy makers. Access to these data will comply with federal requirements that 
ensure the protection of survey participant confidentiality. 
•	 Develop and disseminate a comprehensive agenda for population research to fill the 
gaps between gene discoveries and health benefits of genetic information. The 
agenda will identify potentially fruitful analyses to be conducted by researchers on 
genotype-phenotype correlation, gene-gene and gene-environment interaction and 
various health outcomes. 
•	 Enhance CDC’s informatics and analytic capacity to develop research datasets that 
link relevant genetic test results and NHANES interview, examination, and laboratory 
measurements. Such an enhanced capacity is needed for data management, review, 
quality control, editing, and documentation, production of research datasets, 
developing access modalities that protect confidentiality, support of proposed 














Accelerate Translation Research and Surveillance 
NOPHG will accelerate its initiatives and activities in the areas of translation research and 
surveillance to advance knowledge about the validity, utility, utilization and population health 
impact of genomic applications and family history for improving health and preventing 
disease in well-defined populations or practice settings. The diagram below shows how 
these translation research and surveillance activities are designed to begin to close the gap 
between gene discoveries and the population health goals of prevention, early detection, 
and treatment. 
Intramural Seed Funding for Public 
Health Genomics Research  
To build on the successes of the current 
seed funding initiatives, NOPHG intends to 
accelerate the process of integrating 
genomics into public health investigations  
(e.g., infectious, environmental, 
occupational, injury, MCH and chronic 
diseases) by funding additional initiatives 
through CDC and its partners. These 
initiatives will demonstrate the utility of 
public health genomics research throughout 
CDC programs and will help plant the seeds 
of growth and development across these 
programs. 
Sustainable EGAPP Process 
NOPHG continues to support the evolution of the EGAPP initiative to meet the growing 
challenges of evidence-based synthesis of knowledge on emerging applications of genomic 
technology and the dissemination of that information. With guidance from the HHS 
interagency EGAPP Steering Committee (http://www.egappreviews.org/committee.htm), 
NOPHG will continue to support the independent EGAPP Working Group and the newly 
formed EGAPP Stakeholders Group, as well as survey stakeholders to obtain feedback on 
EGAPP products and process, and continue efforts to enhance partnerships and 
collaborations with similar efforts in the U.S. and globally. 
Genomics for Early Disease Detection and Intervention Initiative (GEDDI) 
NOPHG will work with CDC programs and other partners to develop and evaluate genomic 
applications that use clinical and genomic information, such as familial risk assessment, 
signs and symptoms recognition, and genetic testing to promote the prevention and early 
detection of both traditional genetic disorders and common diseases.
For many years, integration of genomic applications into clinical practice has been focused 
on genetic testing for individually rare single gene disorders. More recently, we are seeing 
the introduction of genomic applications for common chronic diseases—e.g., by using 
genetic markers in early identification of cancer, or targeting therapies based on genotype 
that optimize response and avoid adverse drug reactions. We can expect increasingly rapid 
development of new genetic tests—including those that test multiple genetic markers 


















    
  
  
   
     
      
refine diagnoses, improve risk prediction, and target therapies for both traditional genetic 
disorders as well as common chronic diseases.  
In the meantime, genomic applications already being used in clinical medicine can be 
evaluated at the population level for assessing disease risk, influencing early disease
detection, and providing guidance for disease prevention or management. These 
applications—including familial risk assessment, signs and symptoms recognition, and 
genetic testing—when used as public health strategies, could contribute to improved 
population health. Family history is an important tool for identifying individuals and families 
with genetic susceptibility to common chronic diseases such as coronary heart disease, 
stroke, diabetes and most cancers, as well as the rare single gene disorders like cystic 
fibrosis, sickle cell anemia, hereditary forms of breast and colorectal cancer. As an integral 
part of primary care and preventive medicine, familial risk assessment has the potential to 
identify individuals at risk of disease, those with sub-clinical disease, and those who may 
already be affected but are undiagnosed.  
There are many single gene disorders across the life span that could benefit from early 
disease detection and interventions through a closer partnership between medicine and 
public health. Many affected persons with genetic diseases such as hereditary 
hemochromatosis (HH), familial hypercholesterolemia (FH), and primary immune deficiency 
disorders, for example, are either missed by the health care system or not diagnosed early 
enough for effective and appropriate interventions to work. Thus valuable opportunities for 
disease and disability prevention are lost. A public health approach employing public and 
provider education about symptom recognition, surveillance strategies, screening, and
referral to appropriate services, could be used to enhance existing health care practice 
leading to earlier diagnosis of these disorders. 
Under the GEDDI initiative, NOPHG will take results of translation research and evidence 
based synthesis and use validated information across public health programs. NOPHG will 
work with CDC collaborators and external partners to identify the genomic applications and 
diseases that are ready and most appropriate for a public health approach. 
7.0 Publication List 
This section provides a list of all scientific articles by NOPHG staff published in peer-
reviewed journals in FY2007. 
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